Literature DB >> 8379965

Plasma triglycerides and lipoprotein(a): inverse relationship in a hyperlipidemic Italian population.

J P Werba1, O Safa, G Gianfranceschi, S Michelagnoli, C R Sirtori, G Franceschini.   

Abstract

The relationship between plasma lipoprotein(a) (Lp(a)) levels and other clinical/biochemical variables was investigated in 1200 consecutive hyperlipidemic patients. Plasma Lp(a) concentrations were measured by a sandwich-ELISA method, while the patients were either on diet or diet plus lipid-lowering drugs; 38% of them had a plasma Lp(a) level > 30 mg/dl. The median plasma Lp(a) concentration and the frequency of Lp(a) > 30 mg/dl were significantly lower in individuals with severe hypertriglyceridemia vs. hypercholesterolemics (HC) or mixed hyperlipidemics (M-HLP), but similar to normolipidemic healthy controls. Patients with isolated moderate hypertriglyceridemia had Lp(a) levels intermediate between HC and M-HLP subjects. The in vitro addition of triglyceride-rich lipoproteins to normotriglyceridemic plasma did not affect the Lp(a) measurement. Plasma Lp(a) concentrations in the whole hyperlipidemic population correlated negatively with triglycerides and positively with total cholesterol, HDL-cholesterol and age, being unrelated to either body mass index or lipid-lowering treatment. In HC patients, the presence of tendon xanthomas was associated with twofold higher Lp(a) levels. These findings argue for a regulatory role of triglycerides on plasma Lp(a) levels in hyperlipidemic patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8379965     DOI: 10.1016/0021-9150(93)90117-d

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  7 in total

1.  A prospective study of lipoprotein(a) and risk of coronary heart disease among women with type 2 diabetes.

Authors:  I Shai; M B Schulze; J E Manson; M J Stampfer; N Rifai; F B Hu
Journal:  Diabetologia       Date:  2005-06-22       Impact factor: 10.122

2.  Increased concentrations of serum Lp(a) lipoprotein in patients with primary gout.

Authors:  S Takahashi; T Yamamoto; Y Moriwaki; Z Tsutsumi; K Higashino
Journal:  Ann Rheum Dis       Date:  1995-02       Impact factor: 19.103

Review 3.  Lipoprotein(a): new insights into an atherogenic lipoprotein.

Authors:  W Bartens; C Wanner
Journal:  Clin Investig       Date:  1994-08

4.  Lipoprotein (a) and coronary artery calcification: prospective study assessing interactions with other risk factors.

Authors:  Kwok Leung Ong; Robyn L McClelland; Matthew A Allison; Mary Cushman; Parveen K Garg; Michael Y Tsai; Kerry-Anne Rye; Fatiha Tabet
Journal:  Metabolism       Date:  2021-01-07       Impact factor: 8.694

5.  Rheumatoid factor mediates excess serum lipoprotein(a) for independent association with type 2 diabetes in men.

Authors:  Altan Onat; Evin Ademoğlu; Günay Can; Servet Altay; Ahmet Karagöz; Bayram Köroğlu; Hüsniye Yüksel
Journal:  Anatol J Cardiol       Date:  2014-10-31       Impact factor: 1.596

6.  Characterization of lipoprotein profiles in patients with hypertriglyceridemic Fredrickson-Levy and Lees dyslipidemia phenotypes: the Very Large Database of Lipids Studies 6 and 7.

Authors:  Renato Quispe; Aditya D Hendrani; Behnoud Baradaran-Noveiry; Seth S Martin; Emily Brown; Krishnaji R Kulkarni; Maciej Banach; Peter P Toth; Eliot A Brinton; Steven R Jones; Parag H Joshi
Journal:  Arch Med Sci       Date:  2019-08-22       Impact factor: 3.318

Review 7.  Molecular, Population, and Clinical Aspects of Lipoprotein(a): A Bridge Too Far?

Authors:  Natalie C Ward; Karam M Kostner; David R Sullivan; Paul Nestel; Gerald F Watts
Journal:  J Clin Med       Date:  2019-11-27       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.